Empowered Patient Podcast

Dr. Robert Cobuzzi, CEO, Diffusion Pharmaceuticals describes the evolution of the thinking about treating hypoxia and low oxygen conditions caused by a variety of diseases and conditions.  With modified crocetin derived from the spice saffron harvested from Crocus sativus, Diffusion has come up with a compound Trans-Sodium Crocetinate --TSC--to treat hypoxic conditions related to peripheral artery disease, blockages of peripheral arteries, brain cancer and other types of solid tumors, strokes and respiratory diseases like COVID-19. @diffusionpharma #crocetinate #TSC #hypoxia #hypoxic #lowoxygen #COVID19 Diffusionpharma.com Download the transcript here